By: Sandeep Singh
Brokerages expect the deal to boost Aurobindo Pharma's earnings per share (EPS) by Rs 7-8. Lannett Company has a porfolio of 113 approved abbreviated new drug applications (ANDAs). Its revenue for the past 12 months stands at Rs 2,887 crore.






